^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    WX-UK1

    i
    Other names: WX-UK1, WX UK1
    Associations

    News

    Trials
    Company:
    Heidelberg Pharma, RedHill
    Drug class:
    Serine protease inhibitor, Urokinase-type plasminogen activator inhibitor
    Related drugs:
    Associations

    News

    Trials
    9ms
    Combined Antitumor Effect of the Serine Protease Urokinase Inhibitor Upamostat and the Sphingosine Kinase 2 Inhibitor Opaganib on Cholangiocarcinoma Patient-Derived Xenografts. (PubMed, Cancers (Basel))
    Mouse weights and PAX165 tumor volumes were measured. Tumor volumes in the upamostat, opaganib, and upamostat plus opaganib groups were significantly decreased compared to the control group.
    Journal
    |
    PRSS3 (Serine Protease 3) • PRSS1 (Serine Protease 1) • SPHK1 (Sphingosine Kinase 1)
    |
    Mesupron (upamostat) • WX-UK1 • Yeliva (opaganib)
    2years
    MECHANISTIC EFFECTS OF UPAMOSTAT AND OPAGANIB IN CHOLANGIOCARCINOMA CELL LINES (AASLD 2022)
    Upamostat and its active metabolite WX-UK1 have been shown to inhibit serine proteases. Upamostat and opaganib in combination have significant inhibitory effects on both CCA cell migration and viability in vitro which may prevent tumor progression. Both drugs have an established clinical safety profile and may be effective in targeted treatment of CCA patients.
    Preclinical
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    Mesupron (upamostat) • WX-UK1 • Yeliva (opaganib)